MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012

Mar 5, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-03-01

Reporting Person: Koya Keizo (Sr. VP, Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-01	Common Stock	S	6844	$4.703	Disposed	12999	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2011, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2011.

F2: The shares were sold in multiple transactions at prices ranging from $4.63 to $4.83 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.